Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.34 |
| ▸ | FAP | Q12884 | 3/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21695294 | 0.93 | HDAC3 (0.37) | RAB9AOPRM1OPRD1OPRK1SIRT2 | |
| SCHEMBL17801960 | 0.93 | ITGB1 (0.34) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL16847844 | 0.93 | OPRM1 (0.33) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL22698603 | 0.91 | SIRT2 (0.35) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL17650868 | 0.91 | HDAC3 (0.32) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL20830828 | 0.90 | SIRT2 (0.34) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL19683931 | 0.90 | SIRT2 (0.37) | SIRT2SIRT1SIRT3FAP | |
| SCHEMBL28953170 | 0.89 | SIRT2 (0.38) | SIRT2SIRT1SIRT3FAP | |
| SCHEMBL21695307 | 0.88 | OPRM1 (0.34) | RAB9AOPRM1OPRD1OPRK1PSEN1 | |
| SCHEMBL25092066 | 0.87 | MEN1 (0.37) | RAB9ASIRT2SIRT1SIRT3PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016090050-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | H1-5, H1-4, CD47 | RAB9A 1399/4885OPRM1 2448/4885OPRD1 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.